↓ Skip to main content

Oncotarget

Article Metrics

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

Overview of attention for article published in Oncotarget, February 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 13,892)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
35 Mendeley
Title
Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs
Published in
Oncotarget, February 2018
DOI 10.18632/oncotarget.24384
Pubmed ID
Authors

Derrick S. Haslem, Ingo Chakravarty, Gail Fulde, Heather Gilbert, Brian P. Tudor, Karen Lin, James M. Ford, Lincoln D. Nadauld

Abstract

The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic cancer who received all of their care within a single institution, we evaluated the overall survival and healthcare costs for each patient. We analyzed the outcomes of 22 patients who received genomic testing and targeted therapy (precision oncology) between July 1, 2013 and January 31, 2015, and compared to 22 historically controlled patients (control) who received standard chemotherapy (N = 17) or best supportive care (N = 5). The median overall survival was 51.7 weeks for the targeted treatment group and 25.8 weeks for the control group (P = 0.008) when matching on age, gender, histological diagnosis and previous treatment lines. Average costs over the entire period were $2,720 per week for the targeted treatment group and $3,453 per week for the control group, (P = 0.036). A separate analysis of 1,814 patients with late-stage cancer diagnoses found that those who received a targeted cancer treatment (N = 93) had 6.9% lower costs in the last 3 months of life compared with those who did not. These findings suggest that precision oncology may improve overall survival for refractory cancer patients while lowering average per-week healthcare costs, resource utilization and end-of-life costs.

Twitter Demographics

The data shown below were collected from the profiles of 27 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 29%
Other 6 17%
Student > Master 4 11%
Student > Bachelor 3 9%
Student > Ph. D. Student 3 9%
Other 3 9%
Unknown 6 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 8 23%
Medicine and Dentistry 8 23%
Engineering 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Economics, Econometrics and Finance 2 6%
Other 5 14%
Unknown 6 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 482. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2021.
All research outputs
#35,332
of 20,016,450 outputs
Outputs from Oncotarget
#7
of 13,892 outputs
Outputs of similar age
#1,098
of 290,508 outputs
Outputs of similar age from Oncotarget
#2
of 586 outputs
Altmetric has tracked 20,016,450 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,892 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,508 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 586 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.